MaxCyte, Inc. has announced the acquisition of SeQure Dx, a company specializing in assessing on-target and off-target gene editing for cell and gene therapies. This strategic move enhances MaxCyte's ...
MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the ...
HealthShots on MSN
Common myths about sickle cell disease that can delay diagnosis
Sickle cell disease is one of the most under-recognised yet fatal inherited diseases. It affects thousands of families in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results